FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
RegulatoryapprovedOlumiantPositive
AI Analysis
Summary
FDA approved Lilly's Olumiant (baricitinib) for pediatric patients 12 years and older with severe alopecia areata, supported by positive Phase 3 data from the BRAVE-AA-PEDS trial demonstrating substantial scalp hair regrowth and improvements in eyebrows.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA approval for pediatric patients 12 years of age and older with severe alopecia areata
Importance:8/10
Sentiment:
0.90
FDA approvalpediatric indicationalopecia areataPhase 3 datahair regrowth
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 25, 2026 9:11 PM